Nasdaq gnlx.

Aug 28, 2023 · WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ... Mar 27, 2023 · Genelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ... Jan 26, 2023 · Nasdaq. 14,305.03 +78.81 (+0.55%) ... the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final ... Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ...

WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in ...Web

12. 6. 2023 ... ... (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common ...

WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. As of November 1, 2023, the average one-year price target for ...Genelux (NASDAQ:GNLX) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.WESTLAKE VILLAGE, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023 , the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock September 14, …WebWESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...

Shares of Genelux Corporation ( GNLX 3.11%) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last ...Web

Feb 1, 2023 · Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities). An ...

Genelux has filed to go public with an IPO on the NASDAQ. 1 year ago - SEC. Get a real-time Genelux Corporation (GNLX) stock price quote with breaking news, …Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...WebShares of Genelux ( GNLX 12.02%) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock ...WebGenelux Corporation (GNLX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 11.70 +1.24 (+11.85%) At close: 04:00PM EST. 11.76 +0.06 …WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology …Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for each option strike price and expiration month. call and put options ... Winners. The top five IPOs of 1H 2023 are as follows (as of Jun 30, 2023): Genelux Corporation (GNLX), which went public on Jan 26, 2023, at $6.00 per share and has since increased to $32.72 ...

GNLX | Complete Genelux Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. NASDAQ does not use this value to determine compliance with the listing requirements. Inpixon Common Stock (INPX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global ...WebIn the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.Genelux Corporation Common Stock (GNLX) Real-Time Quotes | Nasdaq Real-Time: GNLX Edit my quotes Genelux Corporation Common Stock (GNLX) 0 Add to Portfolio GNLX GNLX REAL TIME GNLX... WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...

See the latest Genelux Corp stock price (GNLX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Find the latest Earnings Report Date for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Genelux (NASDAQ:GNLX) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ...WESTLAKE VILLAGE, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023 , the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock September 14, …WebWESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, …Check if GNLX Stock has a Buy or Sell Evaluation. GNLX Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Genelux Corporation News.Genelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ...Genelux Co. (NASDAQ:GNLX – Free Report) – Brookline Capital Management reduced their FY2023 earnings per share (EPS) estimates for shares of Genelux in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($1.03) per share for the year, down from their […]HC Wainwright started coverage of Genelux ( NASDAQ: GNLX) with a buy rating, stating that it believed the company’s lead oncolytic virus Olvi-Vec is “underappreciated” and could lead to a ...

WESTLAKE VILLAGE, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023 , the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock September 14, …Web

Oct 5, 2023 · Find the latest historical data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.

In the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...WebNASDAQ GNLX opened at $11.10 on Monday. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98.The latest price target for Genelux ( NASDAQ: GNLX) was reported by Maxim Group on Tuesday, September 12, 2023. The analyst firm set a price target for 40.00 expecting GNLX to rise to within 12 ...WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 ...So far, 2023 has been a great year for Genelux Corporation (NASDAQ: GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily been active in studies pertaining to ovarian cancer. However, Genelux has also been forthcoming about its V2ACT Immunotherapy, which incorporates …In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Bed Bath & Beyond Inc. Common Stock. 1.74%.Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. As of November 1, 2023, the average one-year price target for ...Genelux Corporation (NASDAQ:GNLX) fell 8.1% to $5.65. Genelux announced pricing of $15 million initial public offering of 2.5 million shares of common stock at a price of $6 per share.Genelux Corp Genelux Corp GNLX Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.

Find the latest news headlines from Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. About This Event Genelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for ...Genelux Corp (NASDAQ:GNLX) Benchmark initiated coverage on Genelux with a Speculative Buy rating and announced a price target of $10. The company’s stock has a 52-week high of $13.28 .Instagram:https://instagram. affirm interestdia stokmarathon oil corp. stockrate hike expectations WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...WebFind the latest Insider Activity data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. stocks predictionsjio chinema May 25, 2023 · WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ... dental plans va WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...Nov 27, 2023 · WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ... GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...